» Articles » PMID: 22920732

Monoclonal Antibody Therapeutics: History and Future

Overview
Specialty Pharmacology
Date 2012 Aug 28
PMID 22920732
Citations 140
Authors
Affiliations
Soon will be listed here.
Abstract

Over the last three decades, monoclonal antibodies have made a dramatic transformation from scientific tools to powerful human therapeutics. At present, approximately 30 therapeutic monoclonal antibodies are marketed in the United States and Europe in a variety of indications, with sales in the US alone reaching approximately $18.5 billion in 2010. This review describes how antibody engineering has revolutionized drug discovery and what are considered the key areas for future development in the monoclonal antibody therapy field.

Citing Articles

Ionic liquids as stabilisers of therapeutic protein formulations: a review of insulin and monoclonal antibodies.

Tien S, Kayser V Biophys Rev. 2025; 17(1):89-101.

PMID: 40060006 PMC: 11885717. DOI: 10.1007/s12551-024-01261-y.


Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics.

Ou L, Setegne M, Elliot J, Shen F, Dassama L Chem Rev. 2025; 125(4):2120-2183.

PMID: 39818743 PMC: 11870016. DOI: 10.1021/acs.chemrev.4c00595.


Design of Cell-Penetrating Domain Antibodies via a Genetically Encoded β-Lactam Amino Acid.

Rabb J, Kruse L, Lin Q Angew Chem Int Ed Engl. 2025; 64(9):e202424076.

PMID: 39777952 PMC: 11850181. DOI: 10.1002/anie.202424076.


The Relevance and Implications of Monoclonal Antibody Therapies on Traumatic Brain Injury Pathologies.

Wang P, Okada-Rising S, Scultetus A, Bailey Z Biomedicines. 2025; 12(12.

PMID: 39767605 PMC: 11672875. DOI: 10.3390/biomedicines12122698.


Bidirectional regulation of the cGAS-STING pathway in the immunosuppressive tumor microenvironment and its association with immunotherapy.

Zhang Y, Wang Y, Mu P, Zhu X, Dong Y Front Immunol. 2024; 15:1470468.

PMID: 39464890 PMC: 11502381. DOI: 10.3389/fimmu.2024.1470468.